Screener
Bicara Therapeutics BCAX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs | 161,763 | — |
| Proceeds from exercise of options | 1,582 | 460 |
| Net cash provided by financing activities | 163,345 | 460 |
| Net (decrease)/increase in cash and cash equivalents | 226,777 | (27,646) |
| Cash and cash equivalents at beginning of period | 96,685 | 489,711 |
| Cash and cash equivalents at end of period | $323,462 | $462,065 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for tax | — | $72 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's net change in cash?
- Bicara Therapeutics (BCAX) reported net change in cash of $226.78M in Q1 2026.
- How has Bicara Therapeutics's net change in cash changed year-over-year?
- Bicara Therapeutics's net change in cash increased by 920.3% year-over-year, from -$27.65M to $226.78M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Bicara Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude